Citations

Clear

479 citation(s) found for "Tobias, JS".

(018) CUFF CONUNDRUM: INFLATABLE PENILE PROTHESIS PLACEMENT IN MEN FOLLOWING TRANSCORPORAL ARTIFICIAL URINARY SPHINCTER
Ungerer, G, Seyer, A, Pinkhasov, Alexandr, Ziegelmann, Matthew , Köhler, Tobias , Elliott, Devlin , Elliott, D

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.016 Get It

Abstract Introduction Concerns exist when inflatable penile prosthesis (IPP) surgery is performed following transcorporal artificial urinary sphincter (TC-AUS) due to risk of damaging the AUS cuff during proximal corporal dilation and device placement. Aside from rare case reports, no data exists on outcomes and complications in patients who undergo IPP surgery with existing TC-AUS in place. Objective We aim to describe perioperative complications, infections, revision rates, and device longevity when IPP surgery is performed with existing TC-AUS in place. Methods A retrospective search was conducted to identify all patients who had undergone TC-AUS placement at a single institution from 2015-2023. Patients who had undergone IPP placement following TC-AUS at the same institution were identified. Operative technique for IPP placement was similar to standard IPP surgery with additional care taken to avoid the AUS device and preferential use of electrocautery over sharp dissection. Operatives notes and all patient encounters were reviewed, and data on demographics, operative details, perioperative complications, infections, revision rates, and device longevity were recorded. Results 727 patients underwent TC-AUS placement from 2015-2023. Of these, 13 patients underwent subsequent IPP placement (fig. 1). All patients had history of prostatectomy, and 6 (46%) patients had prior radiation. The median follow-up after IPP was 31.7 months and the time gap between AUS and IPP averaged 18.3 months (range 2.3 to 56.7 months). Average operative time for IPP was 85 minutes (range 53 to 202 minutes). Reservoirs were all placed contralateral to the AUS reservoir to minimize risk of injury to the AUS device. 8 patients had a 12 Fr catheter left post-operatively for less than 24 hours. Proximal dilation was noted to be difficult in 2 patients (15%), both of which were successfully dilated without perforation or damage to the AUS cuff. No infections or erosions occurred. 3 patients (23%) developed mechanical failure at a mean time of 28.7 months following IPP placement (36.5 months after AUS). Cuff leak was identified in 2 patients and the third has yet to undergo revision surgery to determine etiology. Conclusions IPP placement appears safe and effective in men who have previously undergone TC-AUS without increased risk of infection or device erosion. Care should be taken when dilating proximally, though proximal dilation was uneventful in most patients. Mechanical failure rates may be slightly higher compared to patients who have either device alone, and patients should be counseled accordingly. Disclosure No.
(014) THE EVOLUTION OF PATIENT SATISFACTION AND WELL- BEING OVER TIME FOLLOWING INFLATABLE PENILE PROSTHESIS
Bonakdarhashemi, M, Ziegelmann, Matthew , Köhler, Tobias , Pinkhasov, Aaron , Guillen, A, Helo, Sevann

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.012 Get It

Abstract Introduction Penile prosthesis (PP) implantation is associated with high patient satisfaction in patients with medically refractory erectile dysfunction (ED). There remains a paucity in the literature regarding the temporal evolution of patient satisfaction and well-being following PP surgery. Objective We aimed to identify factors responsible for patient satisfaction after surgery. Methods We initiated a registry of patients undergoing surgery for placement of a PP. After consent, perioperative study assessments and follow-ups were conducted. After surgery, patients were directed to a survey at 6 months and 12 months. Patients who completed both items were included in the analysis. Results A total of 304 patients had a PP placement, of these 101 completed the initial surveys. Overall patient satisfaction was favorable and durable and 6- and 12-months (87% and 82% respectively, p = 0.11). Confidence with device use was reported by 92% at 6 months, without significant change at 1 year (vs. 95%, p = 0.91). At 6 months, 81% of patients reported that their PP met or exceeded expectations, 83% of patients reported that they would undergo the procedure again, and 80% would recommend to a friend/family member. [Figure 1] At 6 months, 78 patients (77%) reported a moderate to high improvement in their overall sense of well-being related to their PP. This percentage further increased to 91% at 12-months (p < 0.001). Additionally, 36% of patients reported that they had made significant improvements to their overall lifestyle since receiving the PP, and this increased to 48% by 12 months post-operatively (p = 0.082). Conclusions Penile prosthesis satisfaction is evident and durable as early as 6 months following surgery. Factors such as perceived overall well-being continued to significantly improve past 6 months, and nearly half of patients reported overall lifestyle improvement following surgery. Disclosure Yes, this is sponsored by industry/sponsor: Coloplast. Clarification: Industry funding only - investigator initiated and executed study.
Conserved missense variant pathogenicity and correlated phenotypes across paralogous genes
Bruenger, Tobias , Ivanuk, Alina, Cohen, Stacey , May, Patrick , Lal, Dennis , May, Patrick , Brünger, Tobias , Pérez‐Palma, Eduardo , Montanucci, Ludovica , Smith, Lacey A. , Parthasarathy, Shridhar , Helbig, Ingo , Nothnagel, Michael

Mayo Clinic

No container title available | November 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5434140/v1 Get It

Abstract Background The majority of missense variants in clinical genetic tests are classified as variants of uncertain significance. Prior research has shown that the deleterious effects and the subsequent molecular consequence of variants are often conserved among paralogous protein sequences within a gene family. Here, we systematically quantified on an exome-wide scale if the existence of pathogenic variants in paralogous genes at a conserved position could serve as evidence for the pathogenicity of a new variant. For the gene family of voltage-gated sodium channels where variants and expert-curated clinical phenotypes were available, we also assessed whether phenotype patterns of multiple disorders for each gene were also conserved across variant positions within the gene family. Methods We developed a framework that assesses the presence of pathogenic missense variants located in conserved residues across paralogous genes. We systematically mapped 2.5 million pathogenic and general population variants from the ClinVar, HGMD, and gnomAD databases onto a total of 9,990 genes and aligned them by gene families. We evaluated the quantity of classifiable amino acids by utilizing pathogenic variants identified in databases alone and then compared this assessment to the inclusion of paralogous pathogenic variants. We validated and quantified the evidence of conserved pathogenic paralogous variants in variant pathogenicity classification. Results Considering conserved pathogenic variants in paralogous genes, increased the number of classifiable variants 2.8-fold across the exome, compared to pathogenic variants in the gene of interest alone. The presence of a pathogenic variant in a paralogous gene is associated with a positive likelihood ratio of 8.32 for variant pathogenicity. The likelihood ratio was gene family-specific. Across ten genes encoding voltage-gated sodium channels and 22 expert-curated disorders, we identified cross-paralog correlated phenotypes based on 3D structure spatial position. For example, the established loss-of-function disorders SCN1A-associated Dravet syndrome, SCN2A-associated autism, SCN5A-associated Brugarda Syndrome, and SCN8A-associated neurodevelopmental disorder without seizures were correlated in their spatial variant position on structure. Finally, we show that phenotype integration in paralog variant selection improves variant classification. Conclusion Our results show that paralogous variants, in particular with phenotype information can enhance our understanding of variant effects.
LTBK-01. PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3
Colman, Howard , Walbert, Tobias , Lassman, Andrew B. , Kizilbash, Sani H. , Kamiya-Matsuoka, Carlos, Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren, Butowski, Nicholas , Forsyth, Peter, Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Levin, Victor A. , Kizilbash, Sani H , Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Eoli, Marica , Peereboom, David M. , Strowd, Roy E. , Pellerino, Alessia , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 22, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii1-viii1

10.1093/neuonc/noae165.1301 Get It

Abstract BACKGROUND Recurrent anaplastic astrocytoma (AA), a grade 3 brain cancer, remains an unmet medical need. STELLAR was a phase III randomized, open-label trial of eflornithine (ornithine decarboxylase inhibitor) with lomustine versus lomustine alone, originally for patients with recurrent AA. However, as the WHO definition of AA evolved during trial conduct (e.g., excluding IDH wild-type disease), we determined results in both the original ITT population and by revised molecularly defined WHO 2021 diagnoses in pre-planned analyses. METHOD Key eligibility: age ≥ 18, AA (2016 WHO criteria), first recurrence ≥ 6 months after radiation and temozolomide, KPS ≥ 70, no imaging findings consistent with grade 4 glioblastoma. Stratification: IDH, age, resection extent, and geography. Patients were randomized to Arm A: eflornithine (2.8 g/m2 TID Q 2/3 weeks) with lomustine (90 mg/m2 Q 6 weeks) or Arm B: lomustine (110 mg/m2 Q 6 weeks). Primary endpoint was OS. The pre-specified hazard ratio (HR) goal was 0.667 based on projected median OS (mOS) increase to 18 months from 12 months. RESULTS 343 pts (172/171 Arms A/B) were randomized (105 sites, 8 countries). ITT analysis found no difference between arms (mOS 23.4 vs. 20.3 months, HR = 0.94). However, a pre-specified subset analysis in IDH mutant, 2021 WHO-defined grade 3 astrocytoma (n=194), showed significant improvement with eflornithine (mOS 34.9 vs. 23.5 months, HR = 0.64, log rank p = 0.016) and PFS (15.8 vs. 7.2 months, HR = 0.58, log rank p = 0.015). No difference was observed in the IDH wild-type subset. AEs were consistent with historic data. CONCLUSION There was no difference in OS between arms in the ITT analysis. However, medically meaningful and statistically significant OS and PFS benefits were observed with eflornithine in the pre-planned analysis of patients with molecularly defined 2021 WHO CNS grade 3 astrocytoma.
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Mendez, Joe , Cohen, Adam L. , Eckenstein, Midori, Jensen, Randy L. , Burt, Lindsay , Salzman, Karen L. , Chamberlain, Marc C. , Hsu, Henry H. , Hutchinson, Marguerite, Mrugała, Maciej M. , Pelayo, Michael, Raizer, Jeffrey J. , Reardon, David A. , Sterba, Michael, Walbert, Tobias , Wong, Eric T. , Zhang, Chao , Colman, Howard , Mendez, Joe S , Reardon, David A , Walbert, Tobias , Colman, Howard , IWAMOTO, FABIO MASSAITI , Ligon, Keith L , Plotkin, Scott R. , Puduvalli, Vinay K. , West, Brian L.

Mayo Clinic

Neuro-Oncology Advances | November 19, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae202 | PMID 39734810 Get It

Abstract Background Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indicate that combining radiation therapy (RT) and pexidartinib reduces radiation resistance. We added pexidartinib to standard-of-care RT/temozolomide (TMZ) in patients with newly diagnosed GBM to assess the therapeutic benefit of altering the tumor microenvironment with pexidartinib. Methods In this open-label, dose-escalation, multicenter, Phase 1b/2 trial, pexidartinib was administered in combination with RT/TMZ followed by adjuvant pexidartinib + TMZ. During Phase 1b, pexidartinib was given 5 or 7 days/week at multiple dosing levels. The primary Phase 1b endpoint was the recommended Phase 2 dose (RP2D). Phase 2 patients received the RP2D with the primary endpoint of median progression-free survival (mPFS). Secondary objectives were median overall survival (mOS), pharmacokinetics, and safety. Results The RP2D of pexidartinib was 800 mg/day for 5 days/week during RT/TMZ, followed by 800 mg/day for 7 days/week with adjuvant TMZ. mPFS was 6.7 months (90% CI: 4.5, 11.5) for the modified intention-to-treat population. The actual mOS was 13.1 months (90% CI: 11.5, 24.5), and the mOS corrected for comparison with matched historical controls was 18.8 months (95% CI: 12.6, 28.0). Conclusions This trial established the RP2D of pexidartinib in combination with RT/TMZ and adjuvant TMZ. Pexidartinib was generally safe and well tolerated. Although the study regimen with pexidartinib was not efficacious, pharmacodynamic studies showed modulation of systemic markers that could lead to alteration of the tumor microenvironment.
CTIM-14. EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM)
Elder, J. Bradley , Hanft, Simon , Lee, Ian , Farrell, Christopher , Boockvar, John A. , Kim, Lyndon, Schulder, Michael , Correia, Carlos Eduardo Silva , Ramakrishna, Rohan , Wu, Julian K. , Agarwal, Vijay , Amankulor, Nduka, Evans, Linton T. , Giglio, Pierre , Wu, Kyle C., Wu, Synphen H., Falo, Cristina, Walbert, Tobias , Robin, Adam , Alnahhas, Iyad , Wernicke, A. Gabriella , Aregawi, Dawit , Maurer, Robert, Jeyapalan, Suriya, Magge, Rajiv , Chan, Amy B. W. , Hormigo, Adı́lia , Higgins, Dominique , Moss, Nelson S. , Sherman, Wendy, Neese, Leila, Pennock, Gregory, Scott, Charles , Perez-Olle, Raul , Andrews, David W. , Lee, Ian Y , Zacharia, Brad E. , Wong, Eric T. , Amankulor, Nduka, Bhatia, Ankush , Brennan, Cameron , Gill, Brian J. A. , Sengupta, Soma , ReFaey, Karim , Vojnic, Morana , Ghatan, Saadi , Singer, Samuel , Malik, Athar N. , Patel, Nitesh V. , Chan, Amy, IWAMOTO, FABIO MASSAITI , Dey, Mahua , Neese, Leila

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii88-viii88

10.1093/neuonc/noae165.0347 Get It

Abstract Standard of care (SOC) for ndGBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. IGV-001 is an autologous biologic-device combination immunotherapy for the treatment of ndGBM that consists of autologous GBM tumor cells and an antisense oligonucleotide against IGF-1R mRNA, irradiated and administered via biodiffusion chambers implanted in the abdomen. In a phase 1b study, IGV-001 was well tolerated without unexpected adverse events in subjects with ndGBM. Multiple efficacy signals were observed, including significant improvements in progression-free survival (PFS), overall survival (OS), radiographic evidence of tumor response, and changes in immune response biomarkers. Here, we present early safety data from the phase 2b randomized, multicenter, double-blind, placebo-controlled study (NCT04485949) designed to assess efficacy and safety of IGV-001 in subjects with ndGBM across 20 sites in the United States. After surgical resection, subjects were randomized 2:1 and treated with IGV-001 or placebo followed by SOC. The primary outcome is PFS, defined as the time from randomization to first progression, as determined by blinded central radiology review, or death. Secondary outcomes include OS, defined as the time from randomization to death due to any cause, and safety. As of May 22, 2024, 99 subjects were randomized and 95 implanted with IGV-001 or placebo plus SOC. A total of 39/45 (86.7%) subjects had sufficient follow-up time after initiated treatment with concurrent radiation and temozolomide. Nine of 72 randomized (12.5%) discontinued treatment, including 7 who stopped during the SOC treatment period. None ceased treatment for adverse events, protocol deviations, or death. A total of 11/72 (15.3%) randomized subjects discontinued the study after randomization. A review of blinded safety data did not show any emerging risk and supports no change to the benefit-risk profile of IGV-001 versus placebo. Updated data will be presented.
DNAR-13. LONG TERM FOLLOW-UP OF A LYNCH SYNDROME-ASSOCIATED GLIOBLASTOMA RESISTANT TO STANDARD-OF-CARE CHEMORADIATION
Baykal, Duru, White, Jessica D. , Breen, William G. , Walbert, Tobias , Forsyth, Peter, Piña, Yolanda , Ser, Merve Hazal , Baykal, Duru, White, Jessica D, Parney, Ian F. , Etame, Arnold B. , Macaulay, Robert , Sener, Uğur

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii120-viii120

10.1093/neuonc/noae165.0464 Get It

Abstract BACKGROUND Lynch syndrome is caused by pathogenic germline variants in the DNA mismatch repair (MMR) genes, predisposing individuals to malignancies, including glioblastoma (GBM). MMR-deficient tumors are resistant to monofunctional alkylators such as temozolomide but not to bifunctional alkylators such as the nitrosourea lomustine. Anti-programmed cell death protein 1 (PD1) immune checkpoint inhibitor (ICI) pembrolizumab represents another treatment option, which is approved by the United States Food and Drug Administration (FDA) for the treatment of mismatch repair deficient cancers. METHODS We present a patient with multifocal GBM and Lynch syndrome who experienced rapid progression following standard-of-care chemoradiation, followed by durable responses to lomustine and then to pembrolizumab. RESULTS A 58-year-old man with Lynch syndrome (MSH2 mutation) and prior history of colon cancer presented with seizures. Magnetic resonance imaging (MRI) brain identified right frontal and left parietal masses. Right frontal tumor was resected; pathology was consistent with GBM, IDH wildtype, MGMT-unmethylated. Both lesions were treated with radiation therapy (60 Gy, 30 fractions) with concurrent and adjuvant temozolomide. After two cycles of adjuvant temozolomide, his left parietal tumor progressed and was subtotally resected, followed by four cycles of lomustine (stopped due to myelotoxicity). He remained progression-free for 15 months. Surveillance MRI identified new enhancement involving the left frontal lobe, left periventricular white matter, and right internal auditory canal, concerning for leptomeningeal dissemination. MRI spine identified no additional lesions. Cerebrospinal fluid cytology was negative for tumor cells on two occasions. Patient was treated with pembrolizumab. He remains on treatment with stable disease four months after ICI initiation and 31 months after GBM diagnosis. CONCLUSIONS Patients with MMR-deficient GBM resist standard chemoradiation. Alternatives such as nitrosourea or ICI therapy may achieve durable responses. While data is insufficient to administer these agents as upfront therapy in this specific setting, both should be considered as options for recurrent disease.
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
Moertel, Christopher L. , Hirbe, Angela C. , Shuhaiber, Hans, Bielamowicz, Kevin , Sidhu, Alpa , Viskochil, David , Lokku, Armend, Smith, L. Mary, Foreman, Nicholas K. , Hajjar, Fouad, McNall‐Knapp, Rene , Weintraub, Lauren , Antony, Reuben , Franson, Andrea , Schiff, David , Walbert, Tobias , Ambady, Prakash , Bota, Daniela A. , Campen, Cynthia , Kaur, Gurcharanjeet , Maraka, Stefania , Nevel, Kathryn , Aguilar-Bonilla, Ana , Chagnon, Sarah, Dalvi, Nagma , Gupta, Punita , Khatib, Ziad, Metrock, Laura K. , Roberts, Ryan D. , Sadighi, Zsila , Babovic‐Vuksanovic, Dusica , Investigators, for the ReNeu Trial, Raslan, Ahmed M. , Franson, Andrea T., Walter, Andrew , Schiff, David, Hajjar, Fouad M., Slopis, John M. , Klesse, Laura J., Nghiemphu, Leia, Mrugała, Maciej M. , Schmidt, Mary Lou, Foreman, Nick K., Moots, Paul L., Antony, Rueben, Merrell, Ryan , Chagnon, Sarah, Maraka, Stefania, Khatib, Ziad, Foreman, Nicholas K , Franson, Andrea , Meade, Julia , Walbert, Tobias , Klesse, Laura J , Moots, Paul L , Bornhorst, Miriam , Aguilar-Bonilla, Ana , Gupta, Punita , Metrock, Laura K , Nghiemphu, P Leia , Roberts, Ryan D , Babovic-Vuksanovic, Dusica, Gershon, Timothy R , Hirbe, Angela C , Weber, Michael , Klesse, Laura J. , Bornhorst, Miriam , Nghiemphu, Phioanh L. , Robison, Nathan John , Stapleton, Stacie L. , Gershon, Timothy R. , Investigators, for the ReNeu Trial, Franson, Andrea T., Tine, Brian A. Van , Koschmann, Carl , Schiff, David, Hajjar, Fouad M., Capal, Jamie K. , Gill, Jonathan Benjamin , Klesse, Laura J., Kilburn, Lindsay Baker , Foreman, Nick K., Moots, Paul L., Dhamija, Radhika , Antony, Rueben, Chagnon, Sarah, Maraka, Stefania, Khatib, Ziad

Mayo Clinic

Journal of Clinical Oncology | November 8, 2024 | Volume: 43 | Issue: 6 | Pages: 716-729

10.1200/jco.24.01034 | PMID 39514826 Get It

PURPOSE Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration–approved for adults. METHODS ReNeu is an open-label, multicenter, pivotal, phase IIb trial of mirdametinib in 58 adults (≥18 years of age) and 56 children (2 to 17 years of age) with NF1-PN causing significant morbidities. Patients received mirdametinib capsules or tablets for oral suspension (2 mg/m 2 twice daily, maximum 4 mg twice daily), regardless of food intake, in 3 weeks on/1 week off 28-day cycles. The primary end point was confirmed objective response rate (ORR; proportion of patients with a ≥20% reduction of target PN volume from baseline on consecutive scans during the 24-cycle treatment phase) assessed by blinded independent central review (BICR) of volumetric magnetic resonance imaging. RESULTS Twenty-four of 58 adults (41%) and 29 of 56 children (52%) had a BICR-confirmed objective response during the 24-cycle treatment phase; in addition, two adults and one child had confirmed responses during long-term follow-up. Median (range) target PN volumetric best response was –41% (−90 to 13) in adults and –42% (−91 to 48) in children. Both cohorts reported significant and clinically meaningful improvement in patient- or parent proxy-reported outcome measures of worst tumor pain severity, pain interference, and health-related quality of life (HRQOL) that began early and were sustained during treatment. The most commonly reported treatment-related adverse events were dermatitis acneiform, diarrhea, and nausea in adults and dermatitis acneiform, diarrhea, and paronychia in children. CONCLUSION In ReNeu, the largest multicenter NF1-PN trial reported to date, mirdametinib treatment demonstrated significant confirmed ORRs by BICR, deep and durable PN volume reductions, and early, sustained, and clinically meaningful improvement in pain and HRQOL. Mirdametinib was well-tolerated in adults and children.
Self‐reported physical activity and gait in older adults without dementia: A longitudinal study
Krell‐Roesch, Janina , Syrjanen, Jeremy A. , Moeller, Tobias , Krafft, Jelena , Barisch‐Fritz, Bettina , Kremers, Walter K. , Ali, Farwa, Petersen, Ronald , Vassilaki, Maria , Geda, Yonas E. , Vassilaki, Maria , Geda, Yonas E , Kremers, Walter K , Ali, Farwa , Knopman, David S. , Stein, Thorsten , Wöll, Alexander

Mayo Clinic

Health Science Reports | November 6, 2024 | Volume: 7 | Issue: 11 | Pages: No page available

10.1002/hsr2.70108 | PMID 39507676 Get It

AbstractBackground and AimsPhysical activity (PA) is associated with higher gait speed. We aimed to examine the associations between PA and change in spatial and temporal gait measures as well as fall risk in community‐dwelling individuals free of dementia.MethodsLongitudinal study among 4173 individuals aged ≥50 years (mean age 71 years; 2078 males; median follow‐up 4 years) enrolled in the Mayo Clinic Study of Aging. Self‐reported late‐life PA was used to calculate overall PA and moderate‐vigorous PA (MVPA) scores. Gait was assessed using GAITRite® and Zeno™ systems. Incident falls information was based on diagnostic codes retrieved from medical records. We ran linear mixed effects models to examine associations between z‐scored PA variables and longitudinal gait parameters, adjusted for age, sex, education, body mass index (BMI), medical comorbidities, and including interactions between PA and time since baseline. In secondary analyses, we calculated Cox Proportional hazard models with age as time scale predicting incident falls by PA, adjusting for sex, education, BMI, medical comorbidities, and falls history.ResultsAt baseline, higher PA was associated with higher velocity (overall PA: estimate 2.9935; MVPA: 2.2961; p < 0.001), higher cadence (overall PA: 1.0665; MVPA: 0.9073; p < 0.001), greater stride length (overall PA: 2.0805; MVPA: 1.4726; p < 0.001), shorter double support time (overall PA: −0.0257; MVPA: −0.0205; p < 0.001), and lower stance time variability (overall PA: −0.0204, p < 0.001; MVPA: −0.0152; p = 0.006). Overall PA was longitudinally associated with less decline in cadence, and MVPA with less increase in intraindividual stance time variability. Overall PA (Hazard ratio 0.892, 95% confidence interval 0.828–0.961, p = 0.003) and MVPA (HR 0.901; 95% CI 0.835–0.973, p = 0.008) were associated with a decreased risk of incident falls.ConclusionLate‐life PA was associated with favorable gait outcomes and decreased risk of incident falls. Thus, late‐life PA may help to maintain gait performance and decrease fall risk in old age.
IPP PLAN: A penile implant checklist
Pinkhasov, Alexandr, Byrne, Eileen R. , Köhler, Tobias S.

Mayo Clinic

International Journal of Reconstructive Urology | October 31, 2024 | Volume: 2 | Issue: 2 | Pages: 124-127

10.4103/ijru.ijru_23_24 Get It